Aztreonam Inhalation Solution (AZLI) Safety Study in Children with CF and Chronic Pseudomonas Aeruginosa
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
This is an open-label, multicenter study in children < 13 years of age with Cystic Fibrosis (CF) and chronic Pseudomonas Aeruginosa (PA) infection in the lower airways to look at the safety of treatment with Aztreonam Inhalation Solution (AZLI) given three times daily for three 28 day on/ 28 day off cycles. The total study duration will be approximately 7 months.
1 Days - 12 Years
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.